Marc S. Raab
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marc S. Raab has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Kenneth C. Anderson
LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center and
3 shared publications- Paul Gerard Richardson
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
2 shared publications Sagar Lonial
Emory University, Atlanta, GA
2 shared publications- A. Keith Stewart
Mayo Clinic, Arizona, Scottsdale, AZ
1 shared publication - Angela Dispenzieri
Division of Hematology, Mayo Clinic, Rochester, USA
1 shared publication - Anthony Dick Ho
Heidelberg University
1 shared publication
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , TPS8066
A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
TPS8066 Background: Therapies for multiple myeloma (MM) can slow progression, prolong survival, and reduce symptoms although most patients will relapse. Elotuzumab, a humanized IgG1 immunostimulatory monoclonal antibody targeting SLAMF7, is FDA approved in combination with lenalidomide and dexamethasone in patients with MM who have received 1 to 3 prior therapies; approval was based on the results of the Phase 3 ELOQUENT-2 trial.1 Clinical trials have shown minimal added toxicity when elotuzumab is combined with the immunomodulatory drugs lenalidomide and thalidomide.1,2 Preclinical results of the OPM-2 xenograft model in ICR-SCID mice (previously used to show synergy of lenalidomide and elotuzumab) demonstrated that the combination of elotuzumab and pomalidomide synergize to kill tumor cells in vivo. Methods: This Phase 2, open-label, randomized study (NCT02654132) will evaluate the efficacy of elotuzumab in combination with pomalidomide and dexamethasone vs pomalidomide and dexamethasone alone. Patients with relapsed/refractory MM who have received ≥ 2 prior lines of therapy that included ≥ 2 consecutive cycles of lenalidomide and a proteasome inhibitor alone or in combination are eligible for inclusion. Patients are randomized to receive either pomalidomide/dexamethasone or the investigational combination pomalidomide/dexamethasone/elotuzumab in 28-day cycles. The dosing schedule consists of elotuzumab 10 mg/kg IV on Days 1, 8, 15, and 22 of Cycles 1 and 2 and elotuzumab 20 mg/kg IV on Day 1 of Cycles 3 and thereafter; pomalidomide 4 mg PO on Days 1–21 of each cycle; dexamethasone 40 mg on Days 1, 8, 15, and 22 of each cycle (except on elotuzumab dosing weeks when dosing is 28 mg PO and 8 mg IV; if > 75 years old, dexamethasone dosing is 20 mg or, on elotuzumab dosing weeks, 8 mg PO and 8 mg IV). The primary endpointis progression-free survival; secondary endpointsareobjective response rate and overall survival. Study start is scheduled for February 2016; 114 patients are planned for enrollment. References: 1. Lonial S et al. N Engl J Med 2015;373:621–31. 2. Mateos M et al. Haematologica 2014;99:364–65. Clinical trial information: NCT02654132.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , TPS8066
A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
TPS8066 Background: Therapies for multiple myeloma (MM) can slow progression, prolong survival, and reduce symptoms although most patients will relapse. Elotuzumab, a humanized IgG1 immunostimulatory monoclonal antibody targeting SLAMF7, is FDA approved in combination with lenalidomide and dexamethasone in patients with MM who have received 1 to 3 prior therapies; approval was based on the results of the Phase 3 ELOQUENT-2 trial.1 Clinical trials have shown minimal added toxicity when elotuzumab is combined with the immunomodulatory drugs lenalidomide and thalidomide.1,2 Preclinical results of the OPM-2 xenograft model in ICR-SCID mice (previously used to show synergy of lenalidomide and elotuzumab) demonstrated that the combination of elotuzumab and pomalidomide synergize to kill tumor cells in vivo. Methods: This Phase 2, open-label, randomized study (NCT02654132) will evaluate the efficacy of elotuzumab in combination with pomalidomide and dexamethasone vs pomalidomide and dexamethasone alone. Patients with relapsed/refractory MM who have received ≥ 2 prior lines of therapy that included ≥ 2 consecutive cycles of lenalidomide and a proteasome inhibitor alone or in combination are eligible for inclusion. Patients are randomized to receive either pomalidomide/dexamethasone or the investigational combination pomalidomide/dexamethasone/elotuzumab in 28-day cycles. The dosing schedule consists of elotuzumab 10 mg/kg IV on Days 1, 8, 15, and 22 of Cycles 1 and 2 and elotuzumab 20 mg/kg IV on Day 1 of Cycles 3 and thereafter; pomalidomide 4 mg PO on Days 1–21 of each cycle; dexamethasone 40 mg on Days 1, 8, 15, and 22 of each cycle (except on elotuzumab dosing weeks when dosing is 28 mg PO and 8 mg IV; if > 75 years old, dexamethasone dosing is 20 mg or, on elotuzumab dosing weeks, 8 mg PO and 8 mg IV). The primary endpointis progression-free survival; secondary endpointsareobjective response rate and overall survival. Study start is scheduled for February 2016; 114 patients are planned for enrollment. References: 1. Lonial S et al. N Engl J Med 2015;373:621–31. 2. Mateos M et al. Haematologica 2014;99:364–65. Clinical trial information: NCT02654132.
- 12 February 2009
- Published by American Society of Hematology in Blood
- Vol. 113 (7) , 1513-1521
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling
Targeting protein kinase C (PKC) isoforms by the small molecule inhibitor enzastaurin has shown promising preclinical activity in a wide range of tumor cells. We further delineated its mechanism of action in multiple myeloma (MM) cells and found a novel role of β-catenin in regulating growth and survival of tumor cells. Specifically, inhibition of PKC leads to rapid accumulation of β-catenin by preventing the phosphorylation required for its proteasomal degradation. Microarray analysis and small-interfering RNA (siRNA)–mediated gene silencing in MM cells revealed that accumulated β-catenin activates early endoplasmic reticulum stress signaling via eIF2α, C/EBP-homologous protein (CHOP), and p21, leading to immediate growth inhibition. Furthermore, accumulated β-catenin contributes to enzastaurin-induced cell death. Sequential knockdown of β-catenin, c-Jun, and p73, as well as overexpression of β-catenin or p73 confirmed that accumulated β-catenin triggers c-Jun–dependent induction of p73, thereby conferring MM cell apoptosis. Our data reveal a novel role of β-catenin in endoplasmic reticulum (ER) stress-mediated growth inhibition and a new proapoptotic mechanism triggered by β-catenin on inhibition of PKC isoforms. Moreover, we identify p73 as a potential novel therapeutic target in MM. Based on these and previous data, enzastaurin is currently under clinical investigation in a variety of hematologic malignancies, including MM.
- 12 February 2009
- Published by American Society of Hematology in Blood
- Vol. 113 (7) , 1513-1521
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling
Targeting protein kinase C (PKC) isoforms by the small molecule inhibitor enzastaurin has shown promising preclinical activity in a wide range of tumor cells. We further delineated its mechanism of action in multiple myeloma (MM) cells and found a novel role of β-catenin in regulating growth and survival of tumor cells. Specifically, inhibition of PKC leads to rapid accumulation of β-catenin by preventing the phosphorylation required for its proteasomal degradation. Microarray analysis and small-interfering RNA (siRNA)–mediated gene silencing in MM cells revealed that accumulated β-catenin activates early endoplasmic reticulum stress signaling via eIF2α, C/EBP-homologous protein (CHOP), and p21, leading to immediate growth inhibition. Furthermore, accumulated β-catenin contributes to enzastaurin-induced cell death. Sequential knockdown of β-catenin, c-Jun, and p73, as well as overexpression of β-catenin or p73 confirmed that accumulated β-catenin triggers c-Jun–dependent induction of p73, thereby conferring MM cell apoptosis. Our data reveal a novel role of β-catenin in endoplasmic reticulum (ER) stress-mediated growth inhibition and a new proapoptotic mechanism triggered by β-catenin on inhibition of PKC isoforms. Moreover, we identify p73 as a potential novel therapeutic target in MM. Based on these and previous data, enzastaurin is currently under clinical investigation in a variety of hematologic malignancies, including MM.
- 27 October 2008
- Published by Cambridge University Press (CUP)
- p. 46-63
TREATMENT OF RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA
INTRODUCTION Despite recent advances in therapy, relapsed and refractory multiple myeloma (MM) remains a significant challenge and an area of unmet medical need. Median survival and responses to treatment are characteristically short. Relapsed and refractory MM is defined as patients who achieve at least a minor response (MR) or better followed by relapse and then progress on salvage therapy, or experience progression within 60 days of their last therapy. Successive treatment regimens typically result in progressively shorter response durations, which reflects emerging drug resistance. The observed decrease in response duration may also reflect changes in disease biology within each patient, with tumor cells expressing a more aggressive phenotype, higher proliferative thrust, and lower apoptotic rates. Although several prognostic factors have been identified for newly diagnosed myeloma, factors that retain prognostic value in the context of relapsed/refractory disease remain to be comprehensively defined. Nonetheless, patients with poor risk include those with t(4;14) or t(14;16), deletion 17 or deletion 13, hypodiploidy, high- β2-microglobulin, light-chain disease, immunoglobulin A (IgA) isotype, and low serum albumin; clinical challenges in the relapsed/refractory population include renal failure, extramedullary disease, hyposecretory myeloma, and advanced bone disease. The advent of novel therapies targeting disease biology and tumor microenvironment has significantly improved the prognosis for patients with relapsed and refractory disease. Bortezomib, a first-in-class proteasome inhibitor, and the immunomodulatory agents thalidomide (Thal) and lenalidomide now constitute “backbone” agents in this setting.
- 27 October 2008
- Published by Cambridge University Press (CUP)
- p. 46-63
TREATMENT OF RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA
INTRODUCTION Despite recent advances in therapy, relapsed and refractory multiple myeloma (MM) remains a significant challenge and an area of unmet medical need. Median survival and responses to treatment are characteristically short. Relapsed and refractory MM is defined as patients who achieve at least a minor response (MR) or better followed by relapse and then progress on salvage therapy, or experience progression within 60 days of their last therapy. Successive treatment regimens typically result in progressively shorter response durations, which reflects emerging drug resistance. The observed decrease in response duration may also reflect changes in disease biology within each patient, with tumor cells expressing a more aggressive phenotype, higher proliferative thrust, and lower apoptotic rates. Although several prognostic factors have been identified for newly diagnosed myeloma, factors that retain prognostic value in the context of relapsed/refractory disease remain to be comprehensively defined. Nonetheless, patients with poor risk include those with t(4;14) or t(14;16), deletion 17 or deletion 13, hypodiploidy, high- β2-microglobulin, light-chain disease, immunoglobulin A (IgA) isotype, and low serum albumin; clinical challenges in the relapsed/refractory population include renal failure, extramedullary disease, hyposecretory myeloma, and advanced bone disease. The advent of novel therapies targeting disease biology and tumor microenvironment has significantly improved the prognosis for patients with relapsed and refractory disease. Bortezomib, a first-in-class proteasome inhibitor, and the immunomodulatory agents thalidomide (Thal) and lenalidomide now constitute “backbone” agents in this setting.
- 27 October 2008
- Published by Cambridge University Press (CUP)
Treatment of Multiple Myeloma and Related Disorders
Due to major advances in understanding the biology and pathogenesis of the disease, the management of multiple myeloma is changing rapidly. New diagnostic and prognostic criteria have been introduced, and treatment options are multiplying with high-dose chemotherapy regimens, stem cell transplants, and the development of novel agents and immune-based strategies that target tumor cells directly. This book is aimed at the practitioner who is looking to put these advances into clinical context. It will serve as an up-to-date resource for treatment of myeloma and related disorders. Chapters are written by international authorities and contain color photos, diagrams, and algorithms outlining preferred treatment strategies. Relevant scientific information is integrated throughout, but the focus here is on providing practical therapeutic guidance for oncologists and hematologists caring for myeloma patients. The book covers all myeloma subtypes and related disorders, including amyloidosis, Waldenstrom macroglobulinemia, plasmacytoma, MGUS, and POEMS syndrome.
- 27 October 2008
- Published by Cambridge University Press (CUP)
Treatment of Multiple Myeloma and Related Disorders
Due to major advances in understanding the biology and pathogenesis of the disease, the management of multiple myeloma is changing rapidly. New diagnostic and prognostic criteria have been introduced, and treatment options are multiplying with high-dose chemotherapy regimens, stem cell transplants, and the development of novel agents and immune-based strategies that target tumor cells directly. This book is aimed at the practitioner who is looking to put these advances into clinical context. It will serve as an up-to-date resource for treatment of myeloma and related disorders. Chapters are written by international authorities and contain color photos, diagrams, and algorithms outlining preferred treatment strategies. Relevant scientific information is integrated throughout, but the focus here is on providing practical therapeutic guidance for oncologists and hematologists caring for myeloma patients. The book covers all myeloma subtypes and related disorders, including amyloidosis, Waldenstrom macroglobulinemia, plasmacytoma, MGUS, and POEMS syndrome.
- 1 November 2006
- Vol. 91 (11) , 1555-8
The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
Patients with multiple myeloma and end-stage renal failure on dialysis are frequently not considered eligible for high-dose therapy (HDT) due to higher transplant-related mortality (TRM). Our aim was to evaluate the toxicity and survival of dialysis-dependent patients after HDT with melphalan (100 mg/m(2)) compared to those of patients without renal insufficiency (melphalan 200 mg/m(2)) in a matched pairs analysis of 34 patients. No significant differences were observed between hematologic toxicity, TRM or disease response. Dialysis patients showed comparable event-free and overall survival. They required significantly extended intravenous antibiotic treatment and longer hospitalization. Thus, melphalan 100 mg/m2 is less toxic, yet equally efficient and improves the prognosis of this group of patients.
- 1 November 2006
- Vol. 91 (11) , 1555-8
The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
Patients with multiple myeloma and end-stage renal failure on dialysis are frequently not considered eligible for high-dose therapy (HDT) due to higher transplant-related mortality (TRM). Our aim was to evaluate the toxicity and survival of dialysis-dependent patients after HDT with melphalan (100 mg/m(2)) compared to those of patients without renal insufficiency (melphalan 200 mg/m(2)) in a matched pairs analysis of 34 patients. No significant differences were observed between hematologic toxicity, TRM or disease response. Dialysis patients showed comparable event-free and overall survival. They required significantly extended intravenous antibiotic treatment and longer hospitalization. Thus, melphalan 100 mg/m2 is less toxic, yet equally efficient and improves the prognosis of this group of patients.